Secretome Therapeutics Secures cGMP Manufacturing Partner for Lead Asset STM-01

Secretome Therapeutics has shared an update. The company announced a partnership with Cellipont Bioservices for cGMP manufacturing of the master cell bank for its lead asset, STM-01. Secretome’s CEO indicated that a core objective for 2025 is to produce STM-01 drug product suitable for late-stage clinical testing and potential commercial use, leveraging Cellipont’s specialized cell and gene therapy manufacturing capabilities.

For investors, this partnership signals a key step in Secretome Therapeutics’ transition from early-stage development toward potential pivotal trials and eventual commercialization of STM-01, which targets cardiovascular and related diseases. Securing a cGMP manufacturing partner reduces a critical operational and regulatory risk often faced by advanced therapy developers and may help streamline the company’s clinical timelines. If STM-01 progresses successfully into late-stage trials, having established compliant manufacturing infrastructure could enhance Secretome’s attractiveness to strategic partners or acquirers and support future revenue prospects. At the industry level, the agreement underscores ongoing demand for specialized manufacturing capacity in the cell and gene therapy space, and may position Secretome more competitively among emerging cardiovascular therapy developers.